Based on this combined evidence, we concluded that regorafenib inhibited CCA growth in both in vitro and in vivo experiments, which is very likely via downregulation of MALT1 expression through suppression of the Raf/Erk/Elk-1 pathway. Here, RAF1 is linked to cholangiocarcinoma.